文献速递免疫规划

二价疫苗对肠道病毒71型和柯萨奇病毒16型感染所致手足口病的广泛保护潜力

Potential of a bivalent vaccine for broad protection against enterovirus 71 and coxsackie virus 16 infections causing hand, foot, and mouth disease.
PubMed 文献 · Vaccine · 2023-08-28

手足口病主要由肠道病毒71型(EV71)和柯萨奇病毒16型(CVA16)引起,目前无特效治疗,需开发二价疫苗。本研究在新生hSCARB2转基因小鼠中评估针对EV71 C4a和CVA16的单价及二价疫苗抗血清的保护效果。结果显示单价和二价抗血清均能有效防护EV71 C4a和CVA16感染,二价疫苗可能成为预防手足口病的 promising 策略。

要点

  • 单价和二价抗血清均能有效防护EV71 C4a和CVA16感染。
  • 单价和二价抗血清均降低EV71 C4a脑干病毒载量,未见明显组织损伤。
  • 单价和二价抗血清均显著降低CVA16感染脑干和肌肉病毒含量。

核心结论

  • 单价和二价抗血清被动免疫可有效防护EV71 C4a和CVA16感染。
  • 开发能广泛防护CV和EV感染的二价疫苗可能是预防手足口病的 promising 策略。

研究设计与样本

  • 研究在新生hSCARB2转基因小鼠中评估针对EV71 C4a和CVA16的单价及二价疫苗抗血清的保护效果。
  • 将疫苗免疫制备的抗血清转移至2日龄hSCARB2转基因小鼠,随后感染EV71 C4a或CVA16病毒。

主要发现

  • 单价或二价疫苗产生的抗血清均有效防护EV71 C4a和CVA16感染。
  • 单价和二价抗血清均降低EV71 C4a脑干病毒载量,未见明显组织损伤。
  • CVA16感染时,单价和二价抗血清均显著降低脑干和肌肉病毒含量。

临床怎么用

  • 原文未据此给出临床推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Hand, foot, and mouth disease (HFMD) is a highly contagious viral infection that is mainly caused by enterovirus 71 (EV71) and coxsackievirus 16 (CVA16). As there are no specific therapeutics for HFMD, the development of a bivalent vaccine is required to cover a broad range of infections. In this study, the effectiveness of novel monovalent and bivalent vaccines targeting EV71 C4a and CVA16 was investigated for their ability to prevent viral infections in neonatal human scavenger receptor class B member 2 (hSCARB2) transgenic mice. As hSCARB2 serves as a key viral receptor for EV71, these transgenic mice are susceptible to EV71 strains and facilitate viral binding, internalization, and uncoating processes. Antisera prepared by vaccine immunization were transferred to 2-day-old hSCARB2 transgenic mice, which were then infected with EV71 C4a or CVA16 virus. The antisera generated by each monovalent or bivalent vaccine effectively protected against EV71 C4a and CVA16 infections. The examination of tissue damage and viral contents in various organs indicated that both monovalent and bivalent antisera reduced EV71 C4a viral load in the brainstem, and no significant tissue damage was observed. During CVA16 infection, the monovalent and bivalent antisera significantly reduced viral contents in both the brainstem and muscles. These results suggest that passive immunity by monovalent and bivalent antisera can effectively protect against EV71 C4a and CVA16 infections. Thus, the development of a bivalent vaccine that can provide broad protection against both CV and EV infections may be a promising strategy in preventing HFMD.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Yi EJ, Kim YI, Song JH, et al. Potential of a bivalent vaccine for broad protection against enterovirus 71 and coxsackie virus 16 infections causing hand, foot, and mouth disease. Vaccine. 2023. PMID: 37648607. doi:10.1016/j.vaccine.2023.08.029

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。